Search

Tszfung Jackie Chan

Examiner (ID: 9388, Phone: (571)270-7981 , Office: P/2837 )

Most Active Art Unit
2837
Art Unit(s)
2832, 2837
Total Applications
1062
Issued Applications
736
Pending Applications
111
Abandoned Applications
237

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 19707866 [patent_doc_number] => 20250018008 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-16 [patent_title] => USE OF MESENCEPHALIC ASTROCYTE-DERIVED NEUROTROPHIC FACTOR IN PREPARATION OF DRUG FOR TREATING HERPES SIMPLEX KERATITIS [patent_app_type] => utility [patent_app_number] => 18/523188 [patent_app_country] => US [patent_app_date] => 2023-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18523188 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/523188
USE OF MESENCEPHALIC ASTROCYTE-DERIVED NEUROTROPHIC FACTOR IN PREPARATION OF DRUG FOR TREATING HERPES SIMPLEX KERATITIS Nov 28, 2023 Pending
Array ( [id] => 19067205 [patent_doc_number] => 20240101631 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA-GAMMAC DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER [patent_app_type] => utility [patent_app_number] => 18/484870 [patent_app_country] => US [patent_app_date] => 2023-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38910 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18484870 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/484870
HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA-GAMMAC DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER Oct 10, 2023 Pending
Array ( [id] => 19232196 [patent_doc_number] => 20240189387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS [patent_app_type] => utility [patent_app_number] => 18/468506 [patent_app_country] => US [patent_app_date] => 2023-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49579 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18468506 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/468506
DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS Sep 14, 2023 Pending
Array ( [id] => 19769967 [patent_doc_number] => 20250051393 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATING INTERFERON REGULATORY FACTOR-5 (IRF-5) ACTIVITY [patent_app_type] => utility [patent_app_number] => 18/289943 [patent_app_country] => US [patent_app_date] => 2022-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 73378 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18289943 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/289943
COMPOSITIONS AND METHODS FOR MODULATING INTERFERON REGULATORY FACTOR-5 (IRF-5) ACTIVITY May 8, 2022 Pending
Array ( [id] => 19359305 [patent_doc_number] => 20240261339 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => INSECT PROTEIN COMPOSITION FOR THE PREVENTION AND TREATMENT OF CONDITIONS RELATED TO INTESTINAL OXIDATIVE STRESS DAMAGE [patent_app_type] => utility [patent_app_number] => 18/563879 [patent_app_country] => US [patent_app_date] => 2022-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19079 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18563879 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/563879
INSECT PROTEIN COMPOSITION FOR THE PREVENTION AND TREATMENT OF CONDITIONS RELATED TO INTESTINAL OXIDATIVE STRESS DAMAGE May 1, 2022 Pending
Array ( [id] => 19248700 [patent_doc_number] => 20240199687 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => SUBSTITUTION OF HISTIDINE WITH 2-THIOHISTIDINE IN BIOACTIVE PEPTIDES [patent_app_type] => utility [patent_app_number] => 18/556587 [patent_app_country] => US [patent_app_date] => 2022-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11337 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556587 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/556587
SUBSTITUTION OF HISTIDINE WITH 2-THIOHISTIDINE IN BIOACTIVE PEPTIDES Apr 21, 2022 Pending
Array ( [id] => 19263709 [patent_doc_number] => 20240207406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => METHODS AND COMPOSITIONS COMPRISING MHC CLASS I PEPTIDES [patent_app_type] => utility [patent_app_number] => 18/556054 [patent_app_country] => US [patent_app_date] => 2022-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39062 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -226 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556054 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/556054
METHODS AND COMPOSITIONS COMPRISING MHC CLASS I PEPTIDES Apr 17, 2022 Pending
Array ( [id] => 19233748 [patent_doc_number] => 20240190940 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH Q61K MUTATION [patent_app_type] => utility [patent_app_number] => 18/286911 [patent_app_country] => US [patent_app_date] => 2022-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19544 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18286911 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/286911
HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH Q61K MUTATION Apr 17, 2022 Pending
Array ( [id] => 19281545 [patent_doc_number] => 20240218019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => METHODS AND COMPOSITIONS COMPRISING MHC CLASS I PEPTIDES [patent_app_type] => utility [patent_app_number] => 18/554180 [patent_app_country] => US [patent_app_date] => 2022-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 73762 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -163 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554180 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/554180
METHODS AND COMPOSITIONS COMPRISING MHC CLASS I PEPTIDES Apr 5, 2022 Pending
Array ( [id] => 19170944 [patent_doc_number] => 20240156918 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => GEL BASED ON ANNELID HEMOGLOBIN [patent_app_type] => utility [patent_app_number] => 18/550192 [patent_app_country] => US [patent_app_date] => 2022-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5491 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18550192 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/550192
GEL BASED ON ANNELID HEMOGLOBIN Mar 13, 2022 Pending
Array ( [id] => 19172471 [patent_doc_number] => 20240158445 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES [patent_app_type] => utility [patent_app_number] => 18/278259 [patent_app_country] => US [patent_app_date] => 2022-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28764 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18278259 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/278259
CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES Feb 21, 2022 Pending
Array ( [id] => 16466705 [patent_doc_number] => 20200368242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => USE OF TG02 FOR TREATING GLIOMAS IN PEDIATRIC SUBJECTS [patent_app_type] => utility [patent_app_number] => 16/991863 [patent_app_country] => US [patent_app_date] => 2020-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29157 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16991863 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/991863
Use of TG02 for treating gliomas in pediatric subjects Aug 11, 2020 Issued
Array ( [id] => 16282590 [patent_doc_number] => 20200276192 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => CANCER TREATMENT METHOD [patent_app_type] => utility [patent_app_number] => 16/879664 [patent_app_country] => US [patent_app_date] => 2020-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12790 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16879664 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/879664
CANCER TREATMENT METHOD May 19, 2020 Abandoned
Array ( [id] => 17073722 [patent_doc_number] => 11110101 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-07 [patent_title] => Prostate function support formula [patent_app_type] => utility [patent_app_number] => 16/867386 [patent_app_country] => US [patent_app_date] => 2020-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 3228 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16867386 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/867386
Prostate function support formula May 4, 2020 Issued
Array ( [id] => 16190744 [patent_doc_number] => 20200231593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT [patent_app_type] => utility [patent_app_number] => 16/843729 [patent_app_country] => US [patent_app_date] => 2020-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15281 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16843729 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/843729
SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT Apr 7, 2020 Abandoned
Array ( [id] => 16267220 [patent_doc_number] => 20200268707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => METHODS OF MODULATING PROTEIN EXOCYTOSIS AND USES OF SAME IN THERAPY [patent_app_type] => utility [patent_app_number] => 16/833859 [patent_app_country] => US [patent_app_date] => 2020-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30534 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16833859 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/833859
METHODS OF MODULATING PROTEIN EXOCYTOSIS AND USES OF SAME IN THERAPY Mar 29, 2020 Abandoned
Array ( [id] => 16153701 [patent_doc_number] => 20200215083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => Methods for Treating Heart Transplant Rejection [patent_app_type] => utility [patent_app_number] => 16/822657 [patent_app_country] => US [patent_app_date] => 2020-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4840 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16822657 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/822657
Methods for Treating Heart Transplant Rejection Mar 17, 2020 Abandoned
Array ( [id] => 17306241 [patent_doc_number] => 11207323 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-28 [patent_title] => sGC stimulators [patent_app_type] => utility [patent_app_number] => 16/817830 [patent_app_country] => US [patent_app_date] => 2020-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 150932 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16817830 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/817830
sGC stimulators Mar 12, 2020 Issued
Array ( [id] => 16175438 [patent_doc_number] => 20200222406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS [patent_app_type] => utility [patent_app_number] => 16/741669 [patent_app_country] => US [patent_app_date] => 2020-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16741669 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/741669
METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS Jan 12, 2020 Abandoned
Array ( [id] => 15866161 [patent_doc_number] => 20200140484 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES [patent_app_type] => utility [patent_app_number] => 16/737742 [patent_app_country] => US [patent_app_date] => 2020-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14196 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16737742 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/737742
IBAT inhibitors for the treatment of liver diseases Jan 7, 2020 Issued
Menu